Molecular Partners AG (MOLN)

$6.655

+0.01 (+0.23%)
Rating:
Recommendation:
-
Symbol MOLN
Price $6.655
Beta 0.664
Volume Avg. 0.01M
Market Cap 239.677M
Shares () -
52 Week Range 5.5-32.04
1y Target Est -
DCF Unlevered MOLN DCF ->
DCF Levered MOLN LDCF ->
ROE -
ROA -
Operating Margin -
Debt / Equity 11.82% Neutral
P/E 1.84 Buy
P/B -
Annual
Quarter

Earnings

Consensus EPS

Upgrades & Downgrades

Latest MOLN news


Healthcare
Biotechnology
NASDAQ Global Select

Molecular Partners AG operates as a clinical-stage biopharmaceutical company, focuses on the discovery, development, and commercialization of therapeutic proteins. Its products candidates include Abicipar, a DARPin therapeutic candidate, which is in Phase III clinical trials for the treatment of neovascular wet age-related macular degeneration, as well as for diabetic macular edema; and MP0420, a multi-specific DARPin therapeutic candidate for the SARS-CoV-2 virus. The company develops MP0310, which is in Phase Ia clinical trials for immuno-oncology; MP0317, a tumor-localized immune agonist that activates immune cells in the tumor, which is in Phase I clinical trials; and MP0274 that is in Phase I clinical trials for HER2-positive cancers. It also develops MP0423 for treating COVID-19; MP0533, a CD3 T cell candidate for acute myeloid leukemia; and MP0250 for vascular endothelial growth factor, hepatocyte growth factor, and human serum albumin to increase half-life. Molecular Partners AG has agreements and collaboration with Novartis AG to develop, manufacture, and commercialize DARPin-conjugated radioligand therapies; Amgen SA; Allergan, Inc.; and discovery alliance with AbbVie Inc. in ophthalmology, as well as other third-party collaborators. The company was incorporated in 2004 and is headquartered in Schlieren, Switzerland.